北京瀚通三昆科技有限公司

HemaTone Beijing Science Technology Corporation commenced CRO business operations in 2004. Its aim is to provide a seamless clinical research and development platform through strategizing and synergizing with its established research networks using its valuable knowledge, know-how, resources and experiences in China.

HemaTone is fully supported by a team of high caliber, diligent and dedicated clinical professionals who have many years experience in managing large and small-scale, global and local clinical trials, covering from “first-in-man” to post marketing surveillance for IVD products and medical devices.